We describe the development and evaluation of an indirect immunofluorescence assay (IFA) kit for rapid and sensitive detection of coxsackievirus A2, -4, -5, -6, and -10. This IFA kit was determined to have 95.9 to 100% sensitivity and 95.8 to 97.2% specificity. It also proved to be beneficial in reducing the number of enteroviruses that are untypeable in the clinical virology laboratory.There are more than 90 serotypes (2, 13, 14) of human enteroviruses, and they cause a wide spectrum of acute febrile diseases among infants and children. They also cause aseptic meningitis; respiratory tract illnesses; herpangina; hand, foot, and mouth disease; otitis media; and infections of numerous other organ systems (8,10,14). CDC Taiwan implemented an enterovirus surveillance system after a devastating hand, foot, and mouth disease outbreak in 1998 caused 78 deaths and 405 severe cases (3). To strengthen the enterovirus surveillance and outbreak control, a virology laboratory network with 13 medical centers has been integrated with the system. Clinical laboratories use one of two available diagnostic technologies for enterovirus serotyping: traditional and molecular (4, 8). The traditional method requires reference antisera and relies on virus culture and neutralization tests (5, 9) but is often laborious and time-consuming. The molecular methods that employ PCR and sequencing (11,12) are faster and more accurate but are also less common in clinical laboratories because they require expensive equipment, special technology, and trained personnel. An indirect immunofluorescence assay (IFA) improved upon the traditional method and helped hospital laboratories simply and reliably deal with many clinical specimens (1, 6, 16). Although the molecular approaches are becoming the method of choice in specialized laboratories, for most clinical and hospital laboratories, as well as laboratories in some developing countries, the IFA might be a better choice if only a preliminary serotyping result is required.Although IFA reagents provide considerable convenience in enterovirus diagnostics, coverage by commercial products is limited to only 19 serotypes (16). For example, in the detection of human enterovirus A species, the use of commercial reagents (e.g., those from Chemicon International, Temecula, CA) allows the diagnosis of coxsackievirus A16 (CVA16) and human enterovirus 71 (EV71) only; reagents for the others, including CVA2 to -8, -10, -12, and -14 as well as EV76 and EV89 to -92, are not yet available (13). When clinical laboratories conduct preliminary enterovirus screening tests by employing commercial IFA kits, many serotypes not yet covered by the reagents are reported as untypeable nonpolio enteroviruses (NPEV). An earlier study by Bastis et al. (1) showed that although commercial IFA reagents could identify more than half of the enterovirus isolates tested, a high percentage of isolates were nevertheless being reported as untypeable NPEV. In our virology laboratory network, CDC Taiwan used commercial IFA technology for it...